PMID: 8944587Nov 1, 1996Paper

Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections

Heart
A I GünalC Lüleci

Abstract

Growth factors have been shown to be associated with primary hypertrophic cardiomyopathy. Octreotide, a long acting somatostatin analogue, can prevent the stimulating effect of growth factors and decrease the left ventricular mass in patients with acromegaly. In the light of these results, three patients with primary hypertrophic cardiomyopathy were treated with subcutaneous octreotide (50 micrograms three times a day during the first week and 100 micrograms twice a day for the following three weeks). Initially, two patients were in New York Heart Association class II in and one was in class III. At the end of a four week treatment session all were in class I. There were significant decreases in left ventricular posterior wall thickness, interventricular septum thickness, and left ventricular mass in all three patients. Both left ventricular end diastolic and end systolic diameters had increased in all of the patients at the end of the fourth week. Two of three patients showed improved diastolic filling: their hyperdynamic systolic performance returned to normal. No side effects were observed during octreotide treatment. The considerable improvement obtained with the short term octreotide treatment in patients with primary hype...Continue Reading

References

Jun 1, 1979·The American Journal of Cardiology·B J Maron, S E Epstein
Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·D E CoolR L Margolis
Sep 1, 1990·Drugs·D McAreavey, J I Robertson
Jun 1, 1989·Cancer Treatment Reviews·H ParmarS L Lightman
Apr 1, 1989·Circulation·J E BrushD S Goldstein
Feb 15, 1986·The American Journal of Cardiology·R B DevereuxN Reichek
Jan 1, 1988·Annual Review of Biochemistry·Y Yarden, A Ullrich
Sep 1, 1988·Circulation·C L McIntosh, B J Maron
Mar 26, 1987·The New England Journal of Medicine·B J MaronS E Epstein
Apr 2, 1987·The New England Journal of Medicine·B J MaronS E Epstein
Sep 1, 1986·Journal of the American College of Cardiology·B J MaronW C Roberts
Nov 15, 1994·The American Journal of Cardiology·S L TokgözoğluE Oram
Sep 1, 1993·The Journal of Clinical Endocrinology and Metabolism·B MerolaG Lombardi

❮ Previous
Next ❯

Citations

Mar 22, 2013·Indian Journal of Ophthalmology·Ozge EvrenKadir Ates
Aug 23, 2002·Acta Ophthalmologica Scandinavica·U CelikerH Celiker
Oct 4, 2005·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Hua YangHarry Rakowski
Jan 18, 2017·Cellular and Molecular Life Sciences : CMLS·Alexander WidiapradjaScott P Levick
Oct 7, 2005·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Brian Schreiber
Sep 22, 2000·The Journal of Clinical Endocrinology and Metabolism·A ColaoG Lombardi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
J E RobertsonD Holmes
© 2021 Meta ULC. All rights reserved